Kezar Life Sciences's market cap is currently ―. The company's EPS TTM is €; its P/E ratio is ―; Kezar Life Sciences is scheduled to report earnings on May 9, 2024, and the estimated EPS forecast is €-0.31. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	-	$ 7.00M	-	-	-
Gross Profit	-	$ 7.00M	-	-	-
EBIT	$ -32.66M	$ -22.71M	$ -23.92M	$ -21.83M	$ -20.03M
EBITDA	$ -32.66M	$ -24.14M	$ -25.43M	$ -23.22M	$ -21.62M
Net Income Common Stockholders	$ -32.26M	$ -23.10M	$ -24.31M	$ -22.20M	$ -18.18M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 201.37M	$ 218.21M	$ 236.59M	$ 257.67M	$ 276.56M
Total Assets	$ 221.24M	$ 249.33M	$ 263.38M	$ 284.18M	$ 299.57M
Total Debt	$ 18.93M	$ 19.55M	$ 20.15M	$ 20.72M	$ 21.26M
Net Debt	$ -182.44M	$ -198.65M	$ -216.44M	$ -236.95M	$ -255.30M
Total Liabilities	$ 33.66M	$ 33.33M	$ 31.10M	$ 31.69M	$ 29.70M
Stockholders Equity	$ 187.57M	$ 215.99M	$ 232.28M	$ 252.49M	$ 269.87M
Cash Flow	-
Free Cash Flow	$ -18.98M	$ -20.34M	$ -22.98M	$ -21.16M	$ -16.23M
Operating Cash Flow	$ -18.98M	$ -20.20M	$ -21.60M	$ -20.86M	$ -15.88M
Investing Cash Flow	$ 27.88M	$ 18.57M	$ 13.20M	$ 16.39M	$ -8.66M
Financing Cash Flow	$ 59.00K	$ 43.00K	$ 382.00K	$ 154.00K	$ 506.00K

Currency in USD

Kezar Life Sciences Earnings and Revenue History

Income Statement >

Kezar Life Sciences Debt to Assets

Balance Sheet >

Kezar Life Sciences Cash Flow

Cash Flow >

Kezar Life Sciences Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing